Anna Norhammar

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ESC HEART FAILURE. 2024;11(3):1377-1388
Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort
Sundstrom J; Arnlov J; Karayiannides S; Bodegard J; Ersmark K; Gustafsson S; Cars T; Svensson MK; Norhammar A
Article: BMJ OPEN. 2024;14(4):e074064
Are there lost opportunities in chronic kidney disease? A region-wide cohort study
Sundstrom J; Norhammar A; Karayiannides S; Bodegard J; Gustafsson S; Cars T; Svensson ME; Arnlov J
Article: LAKARTIDNINGEN. 2024;121:23130
[Diabetes and periodontitis - common, important but often neglected].
Norhammar A; Gustafsson A; Rydén L; Brismar K
Article: LAKARTIDNINGEN. 2024;121:23137
[Periodontitis - an often neglected risk factor for several other diseases].
Gustafsson A; Norhammar A; Klinge B; Rydén L
Article: DIABETES CARE. 2024;66(SUPPL 1):S493
High mannose correlates with surrogate indexes of insulin resistance and predicts cardiovascular events independently of glycaemic status and traditional risk factors
Fortin E; Campi B; Ferrannini E; Mari A; Mellbin L; Norhammar A; Nasman P; Ryden L; Saba A; Ferrannini G
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):25
Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states
Riccio A; Fortin E; Mellbin L; Norhammar A; Naesman P; Ryden L; Sesti G; Ferrannini G
Article: INTERNATIONAL ENDODONTIC JOURNAL. 2024;57(1):12-22
Primary apical periodontitis correlates to elevated levels of interleukin-8 in a Swedish population: A report from the PAROKRANK study
Sebring D; Kvist T; Lund H; Jonasson P; Lira-Junior R; Norhammar A; Ryden L; Buhlin K
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2023;37(10):108599
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial
Ritsinger V; Hagstrom E; Hambraeus K; James S; Jernberg T; Lagerqvist B; Leosdottir M; Lundman P; Pernow J; Ostlund O; Norhammar A
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):208
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia Experiences from the randomized, controlled SOCOGAMI trial
Fortin E; Lundin M; Mellbin L; Norhammar A; Naesman P; Smetana S; Soerensson P; Ferrannini E; Ryden L; Ferrannini G
Article: BMJ OPEN. 2023;13(5):e069770
Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006-2019: a registry-based cohort study
Leosdottir M; Hagstrom E; Hadziosmanovic N; Norhammar A; Lindahl B; Hambraeus K; Jernberg T; Back M
Article: BMJ OPEN. 2023;13(4):e069037
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case-control study
Ritsinger V; Bodegard J; Kristofi R; Thuresson M; Nathanson D; Nystrom T; Eriksson J; Norhammar A
Article: HEART. 2023;109(7):548-556
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Norhammar A; Bodegard J; Vanderheyden M; Tangri N; Karasik A; Maggioni AP; Sveen KA; Taveira-Gomes T; Botana M; Hunziker L; Thuresson M; Banerjee A; Sundstrom J; Bollmann A
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2022;56(1):337-342
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK
Ferrannini G; Almosawi M; Buhlin K; De Faire U; Kjellstrom B; Klinge B; Nygren A; Nasman P; Svenungsson E; Ryden L; Norhammar A
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):282
Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
Kristofi R; Bodegard J; Ritsinger V; Thuresson M; Nathanson D; Nystrom T; Norhammar A; Eriksson JW
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;193:110141
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)
Lundin M; Ferrannini G; Mellbin L; Johansson I; Norhammar A; Nasman P; Shahim B; Smetana S; Venkateshvaran A; Wang A; Sorensson P; Ryden L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (EJPC). 2022;29(13):1759-1769
Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study
Karayiannides S; Norhammar A; Landstedt-Hallin L; Friberg L; Lundman P
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):195
Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Nasman P; Saba A; Ferrannini E; Ryden L
Article: DIABETES CARE. 2022;45(9):2111-2117
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population
Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Ryden L
Article: JOURNAL OF PERIODONTOLOGY. 2022;93(9):1325-1335
Association of peptidoglycan recognition protein 1 to post-myocardial infarction and periodontal inflammation: A subgroup report from the PAROKRANK (Periodontal Disease and the Relation to Myocardial Infarction) study
Rathnayake N; Gustafsson A; Sorsa T; Norhammar A; Bostanci N
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):129
Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort
Meziani S; Ferrannini G; Bjerre M; Hansen TK; Ritsinger V; Norhammar A; Gyberg V; Nasman P; Ryden L; Mellbin LG
Article: DIABETES, OBESITY AND METABOLISM. 2022;24(7):1277-1287
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Norhammar A; Bodegard J; Eriksson JW; Haller H; Linssen GCM; Banerjee A; Karasik A; Mamouris P; Tangri N; Taveira-Gomes T; Maggioni AP; Botana M; Thuresson M; Okami S; Yajima T; Kadowaki T; Birkeland KI
Article: UPSALA JOURNAL OF MEDICAL SCIENCES. 2022;127(1)
Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study
Svensson MK; Vilela FS; Leosdottir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
Article: INTERNATIONAL ENDODONTIC JOURNAL. 2022;55(1):6-17
Endodontic inflammatory disease: A risk indicator for a first myocardial infarction
Sebring D; Buhlin K; Norhammar A; Ryden L; Jonasson P; Lund H; Kvist T
Article: ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY AND ORAL RADIOLOGY. 2022;133(1):88-99
Association of high cardiovascular risk and diabetes with calcified carotid artery atheromas depicted on panoramic radiographs
Gustafsson N; Ahlqvist J; Norhammar A; Naslund U; Ryden L; Wester P; Jaghagen EL
Article: JOURNAL OF PERIODONTOLOGY. 2021;92(12):1730-1737
Periodontitis, assessed using periodontal treatment as a surrogate marker, has no association with a first myocardial infarction in a Swedish population
Nordendahl E; Fored M; Kjellstrom B; Ekbom A; Norhammar A; Gustafsson A
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):227
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
Lind V; Hammar N; Lundman P; Friberg L; Talback M; Walldius G; Norhammar A
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2021;10(22):e022667
Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes
Ritsinger V; Hagstrom E; Lagerqvist B; Norhammar A
Article: EUROPEAN HEART JOURNAL - QUALITY OF CARE AND CLINICAL OUTCOMES. 2021;7(5):431-437
The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)
Back M; Leosdottir M; Hagstrom E; Norhammar A; Hag E; Jernberg T; Wallentin L; Lindahl B; Hambraeus K
Article: EUROPEAN HEART JOURNAL OPEN. 2021;1(2):oeab023
Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction.
Wang A; Flanagan J; Arver S; Norhammar A; Näsman P; Rydén L; Mellbin LG
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2021;23(9):1499-1511
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):159
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh S-Y; Chiang C-E; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jorgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegard J; Surmont F; Fenici P
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;177:108822
Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries
Johansson I; Norhammar A
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):122
Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c
Karayiannides S; Djupsjo C; Kuhl J; Hofman-Bang C; Norhammar A; Holzmann MJ; Lundman P
Article: DIABETES, OBESITY AND METABOLISM. 2021;23(6):1431-1435
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study
Lam CSP; Karasik A; Melzer-Cohen C; Cavender MA; Kohsaka S; Norhammar A; Thuresson M; Chen H; Wittbrodt E; Fenici P; Kosiborod M
Article: DIABETES CARE. 2021;44(5):1211-1218
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
Kristofi R; Bodegard J; Norhammar A; Thuresson M; Nathanson D; Nystrom T; Birkeland KI; Eriksson JW
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2021;330:23-29
Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study
Santos-Pardo I; Lagerqvist B; Ritsinger V; Witt N; Norhammar A; Nystrom T
Article: EUROPEAN HEART JOURNAL (EHJ) - CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(2):104-111
Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
Trevisan M; Fu EL; Szummer K; Norhammar A; Lundman P; Wanner C; Sjoelander A; Jernberg T; Carrero JJ
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):38
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Ryden L
Article: DIABETES, OBESITY AND METABOLISM. 2021;23(1):75-85
Lower cardiorenal risk withsodium-glucosecotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Birkeland KI; Bodegard J; Banerjee A; Kim DJ; Norhammar A; Eriksson JW; Thuresson M; Okami S; Ha KH; Kossack N; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2020;17(6):1479164120973676
Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry
Ritsinger V; Lagerqvist B; Lundman P; Hagstrom E; Norhammar A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (EJPC). 2020;27(17):1890-1901
Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry
Ritsinger V; Nystrom T; Saleh N; Lagerqvist B; Norhammar A
Article: DIABETES CARE. 2020;43(9):2001-2009
Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
Ferrannini G; Norhammar A; Gyberg V; Mellbin L; Ryden L
Article: DIABETES, OBESITY AND METABOLISM. 2020;22(9):1607-1618
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Birkeland KI; Bodegard J; Eriksson JW; Norhammar A; Haller H; Linssen GCM; Banerjee A; Thuresson M; Okami S; Garal-Pantaler E; Overbeek J; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
Article: THE LANCET DIABETES AND ENDOCRINOLOGY. 2020;8(7):606-615
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jorgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomaki J; Karasik A; Goh S-Y; Chiang C-E; Thuresson M; Chen H; Wittbrodt E; Bodegard J; Surmont F; Fenici P; Kosiborod M
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2020;17(3):1479164120922123-147916412092212
Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?
Ferrannini G; Svenungsson E; Kjellstrom B; Elvin K; Grosso G; Nasman P; Ryden L; Norhammar A
Article: EUROPEAN HEART JOURNAL. 2020;41(2):255-323
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Jüni P; Lettino M; Marx N; Mellbin LG; Östgren CJ; Rocca B; Roffi M; Sattar N; Seferović PM; Sousa-Uva M; Valensi P; Wheeler DC; ESC Scientific Document Group
Article: DIABETES, OBESITY AND METABOLISM. 2019;21(12):2651-2659
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
Norhammar A; Bodegard J; Nystrom T; Thuresson M; Rikner K; Nathanson D; Eriksson JW
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2019;16(6):582-584
Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study
Ritsinger V; Jensen J; Ohm D; Omerovic E; Koul S; Frobert O; Erlinge D; James S; Lagerqvist B; Norhammar A
Article: DIABETES CARE. 2019;42(8):1504-1511
Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study
Norhammar A; Kjellstrom B; Habib N; Gustafsson A; Klinge B; Nygren A; Nasman P; Svenungsson E; Ryden L
Article: DIABETES, OBESITY AND METABOLISM. 2019;21(5):1136-1145
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Norhammar A; Bodegard J; Nystrom T; Thuresson M; Nathanson D; Eriksson JW
Article: DIABETES, OBESITY AND METABOLISM. 2019;21(4):968-974
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2019;16(1):22-27
Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort
Smaradottir MI; Catrina S-B; Brismar K; Norhammar A; Gyberg V; Mellbin LG
Article: PHARMACOECONOMICS - OPEN. 2018;2(4):393-402
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014
Nathanson D; Sabale U; Eriksson JW; Nystrom T; Norhammar A; Olsson U; Bodegard J
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2018;15(6):494-503
Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function
Johansson I; Dahlstrom U; Edner M; Nasman P; Ryden L; Norhammar A
Article: ENDOCRINOLOGY, DIABETES & METABOLISM. 2018;1(4):e00036
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Persson F; Bodegard J; Lahtela JT; Nystrom T; Jorgensen ME; Jensen ML; Gulseth HL; Thuresson M; Hoti F; Nathanson D; Norhammar A; Birkeland KI; Eriksson JG; Eriksson JW
Article: JOURNAL OF DENTAL RESEARCH. 2018;97(10):1100-1105
Invasive Dental Treatment and Risk for a First Myocardial Infarction
Nordendahl E; Kjellstrom B; Fored CM; Ekbom A; Svensson T; Norhammar A; Gustafsson A
Article: JOURNAL OF DENTAL RESEARCH. 2018;97(10):1114-1121
Severe Periodontitis Is Associated with Myocardial Infarction in Females
Nordendahl E; Gustafsson A; Norhammar A; Nasman P; Ryden L; Kjellstrom B
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2018;15(5):387-395
Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort
Ritsinger V; Brismar K; Mellbin L; Nasman P; Ryden L; Soderberg S; Norhammar A
Article: DIABETES, OBESITY AND METABOLISM. 2018;20(8):1983-1987
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jorgensen ME; Wittbrodt ET; Thuresson M; Bodegard J; Hammar N; Fenici P
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2018;71(22):2497-2506
SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL
Cavender MA; Norhammar A; Birkeland KI; Jorgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegard J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M
Article: DIABETES CARE. 2018;41(4):876-883
Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report
Ritsinger V; Hero C; Svensson A-M; Saleh N; Lagerqvist B; Eeg-Olofsson K; Norhammar A
Article: DIABETES, OBESITY AND METABOLISM. 2018;20(2):344-351
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Persson F; Nystrom T; Jorgensen ME; Carstensen B; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Eriksson JW; Norhammar A; Bodegard J; Birkeland KI
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2018;15(1):31-38
High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report
Karayiannides S; Lundman P; Friberg L; Norhammar A
Article: THE LANCET DIABETES AND ENDOCRINOLOGY. 2017;5(9):709-717
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Birkeland KI; Jorgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nystrom T; Eriksson JW; Bodegard J; Norhammar A
Article: EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING. 2017;16(6):468-474
Symptoms of depression and their relation to myocardial infarction and periodontitis
Kjellstrom B; Gustafsson A; Nordendal E; Norhammar A; Nygren A; Nasman P; Ryden L; Asberg M
Article: CIRCULATION. 2017;136(3):249-259
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jorgensen ME; Thuresson M; Arya N; Bodegard J; Hammar N; Fenici P
Article: JOURNAL OF CLINICAL PERIODONTOLOGY. 2017;44(7):692-699
Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients
Rathnayake N; Buhlin K; Kjellstrom B; Klinge B; Lowbeer C; Norhammar A; Ryden L; Sorsa T; Tervahartiala T; Gustafsson A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (EJPC). 2017;24(3_suppl):52-60
Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
Norhammar A; Mellbin L; Cosentino F
Article: DIABETES, OBESITY AND METABOLISM. 2017;19(6):831-841
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetese
Nystrom T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (EJPC). 2017;24(8):848-857
Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: A nationwide study
Ritsinger V; Hero C; Svensson AM; Saleh N; Lagerqvist B; Eeg-Olofsson K; Norhammar A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2017;14(2):77-87
Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
Ritsinger V; Brismar K; Malmberg K; Mellbin L; Nasman P; Ryden L; Soderberg S; Tenerz A; Norhammar A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2017;14(2):69-76
Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort
Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Nasman P; Mellbin LG
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2017;123:199-208
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Nystrom T; Bodegard J; Nathanson D; Thuresson M; Norhammard A; Eriksson JW
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2016;68(13):1404-1416
Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
Johansson I; Dahlstrom U; Edner M; Nasman P; Ryden L; Norhammar A
Article: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. 2016;14(9):987-989
Periodontal disease - important to consider in cardiovascular disease prevention.
Kjellström B; Rydén L; Klinge B; Norhammar A
Article: DIABETOLOGIA. 2016;59(8):1692-1701
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Norhammar A; Bodegard J; Nystrom T; Thuresson M; Eriksson JW; Nathanson D
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2016;117:39-47
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nystrom T; Norhammare A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2016;13(4):307-311
Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study
Arnetz L; Hage C; Brismar K; Catrina S-B; Norhammar A; Lundman P; Wallander M; Ryden L; Mellbin L
Article: CIRCULATION. 2016;133(6):576-583
Periodontitis Increases the Risk of a First Myocardial Infarction A Report From the PAROKRANK Study
Ryden L; Buhlin K; Ekstrand E; de Faire U; Gustafsson A; Holmer J; Kjellstrom B; Lindahl B; Norhammar A; Nygren A; Nasman P; Rathnayake N; Svenungsson E; Klinge B
Article: GROWTH HORMONE AND IGF RESEARCH. 2015;25(6):298-303
Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity
Arnetz L; Hage C; Ekberg NR; Alvarsson M; Brismar K; Norhammar A; Mellbin L
Article: HEART. 2015;101(14):1139-1148
Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes
Johansson I; Dahlstrom U; Edner M; Nasman P; Ryden L; Norhammar A
Article: CIRCULATION: CARDIOVASCULAR INTERVENTIONS. 2015;8(6):e002328
High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus Results From the Swedish Coronary Angiography and Angioplasty Registry
Ritsinger V; Saleh N; Lagerqvist B; Norhammar A
Article: PLOS ONE. 2015;10(7):e0126370
Salivary Matrix Metalloproteinase-8 and-9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease)
Rathnayake N; Gustafsson A; Norhammar A; Kjellstrom B; Klinge B; Ryden L; Tervahartiala T; Sorsa T
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2015;12(1):23-32
Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Longterm follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
Ritsinger V; Tanoglidi E; Malmberg K; Nasman P; Ryden L; Tenerz A; Norhammar A
Article: THE LANCET DIABETES AND ENDOCRINOLOGY. 2014;2(8):627-633
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial
Ritsinger V; Malmberg K; Martensson A; Ryden L; Wedel H; Norhammar A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2014;11(4):290-293
The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study
Hage C; Brismar K; Lundman P; Norhammar A; Ryden L; Mellbin L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2014;16(4):409-418
Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry
Johansson I; Edner M; Dahlstrom U; Nasman P; Ryden L; Norhammar A
Article: DIABETOLOGIA. 2012;55(8):2109-2117
Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment
Saleh N; Petursson P; Lagerqvist B; Skuladottir H; Svensson A; Eliasson B; Gudbjornsdottir S; Eeg-Olofsson K; Norhammar A
Article: DIABETOLOGIA. 2011;54(6):1308-1317
Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Ryden L
Article: JOURNAL OF INTERNAL MEDICINE. 2010;268(1):75-82
Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes
Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Ryden L
Article: EUROINTERVENTION. 2010;5(8):891-897
Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry
Norhammar A; Lagerqvist B; Saleh N
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2009;6(2):71-79
Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study
Hage C; Norhammar A; Grip L; Malmberg K; Sarkar N; Svane B; Ryden L
Article: HEART. 2008;94(12):1565-1570
Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA)
Norhammar A; Stenestrand U; Lindback J; Wallentin L
Article: DIABETIC MEDICINE. 2008;25(8):949-955
Leptin -: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes
Wallander M; Soderberg S; Norhammar A
Article: DIABETES CARE. 2008;31(1):36-38
Oral glucose tolerance test:: A reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice -: A report on repeated oral glucose tolerance tests from the GAMI Study
Wallander M; Ryden L; Malmberg K; Tenerz A; Norhammar A
Article: EUROPEAN HEART JOURNAL. 2008;29(2):166-176
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Ryden L
Article: HEART. 2007;93(12):1577-1583
Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus:: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission
Norhammar A; Lindback J; Ryden L; Wallentin L; Stenestrand U
Article: DIABETES CARE. 2007;30(9):2343-2348
IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes
Wallander M; Norhammar A; Malmberg K; Ohrvik J; Ryden L; Brismar K
Article: DIABETOLOGIA. 2006;49(10):2247-2255
Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction
Wallander M; Brismar K; Ohrvik J; Ryden L; Norhammar A
Article: DIABETES AND VASCULAR DISEASE RESEARCH. 2006;3(1):52-56
Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty.
Yngen M; Norhammar A; Hjemdahl P; Wallén NH
Article: DIABETOLOGIA. 2005;48(11):2229-2235
Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes:: a report from the GAMI study
Wallander M; Bartnik M; Efendic S; Hamsten A; Malmberg K; Öhrvik J; Rydén L; Silveira A; Norhammar A
Article: EUROPEAN HEART JOURNAL. 2004;25(22):1990-1997
Newly detected abnormal glucose tolerance:: an important predictor of long-term outcome after myocardial infarction
Bartnik M; Malmberg K; Norhammar A; Tenerz Å; Öhrvik J; Rydén L
Article: JOURNAL OF INTERNAL MEDICINE. 2004;256(4):288-297
Abnormal glucose tolerance -: a common risk factor in patients with acute myocardial infarction in comparison with population-based controls
Bartnik M; Malmberg K; Hamsten A; Efendic S; Norhammar A; Silveira A; Tenerz Å; Öhrvik J; Rydén L
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2004;43(4):585-591
Diabetes mellitus:: The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization
Norhammar A; Malmberg K; Diderholm E; Lagerqvist B; Lindahl B; Rydén L; Wallentin L
Article: DIABETES CARE. 2003;26(10):2770-2776
Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes
Tenerz Å; Norhammar A; Silveira A; Hamsten A; Nilsson G; Rydén L; Malmberg K
Article: EUROPEAN HEART JOURNAL. 2003;24(9):838-844
Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction
Norhammar A; Malmberg K; Rydén L; Tornvall P; Stenestrand U; Wallentin L
Article: EUROPEAN HEART JOURNAL, SUPPLEMENT. 2003;5(B):B29-B31
Managing heart disease - Acute coronary syndromes: meticulous care is life-saving
Norhammar A
Article: THE LANCET. 2002;359(9324):2140-2144
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study
Norhammar A; Tenerz Å; Nilsson G; Hamsten A; Efendíc S; Rydén L; Malmberg K
Article: DIABETES CARE. 1999;22(11):1827-1831
Admission plasma glucose - Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients
Norhammar AM; Rydén L; Malmberg K
Article: CIRCULATION. 1999;99(20):2626-2632
Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction - Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study
Malmberg K; Norhammar A; Wedel H; Rydén L
Visa fler

Alla övriga publikationer

Letter: DIABETES, OBESITY AND METABOLISM. 2023;25(8):2402-2409
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study
Goh S-YN; Kosiborod M; Lam CSPA; Cavender M; Kohsaka S; Norhammar A; Birkeland KIW; Holl R; Mauricio D; Tangri NE; Shaw J; Thuresson M; Fenici P; Kim DJ
Review: ESC HEART FAILURE. 2022;9(5):2767-2778
Impact analysis of heart failure across European countries: an ESC-HFA position paper
Rosano GMC; Seferovic P; Savarese G; Spoletini I; Lopatin Y; Gustafsson F; Bayes-Genis A; Jaarsma T; Abdelhamid M; Miqueo AG; Piepoli M; Tocchetti CG; Ristic AD; Jankowska E; Moura B; Hill L; Filippatos G; Metra M; Milicic D; Thum T; Chioncel O; Ben Gal T; Lund LH; Farmakis D; Mullens W; Adamopoulos S; Bohm M; Norhammar A; Bollmann A; Banerjee A; Maggioni AP; Voors A; Solal AC; Coats AJS
Letter: DIABETES CARE. 2020;43(1):E9
Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511
Norhammar A; Kjellstroem B; Habib N; Gustafsson A; Klinge B; Nygren A; Naesman P; Svenungsson E; Ryden L
Letter: ANNALS OF INTERNAL MEDICINE. 2019;170(4):277-280
Antiphospholipid Antibodies in Patients With Myocardial Infarction
Grosso G; Sippl N; Kjellstrom B; Amara K; de Faire U; Elvin K; Lindahl B; Nasman P; Ryden L; Norhammar A; Svenungsson E
Letter: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2018;72(12):1427-1428
Prognosis in Patients With Diabetes Mellitus and STEMI Undergoing Primary PCI
Karayiannides S; Norhammar A; Frobert O; James SK; Lagerqvist B; Lundman P
Editorial comment: THE LANCET DIABETES AND ENDOCRINOLOGY. 2018;6(7):517-519
Diabetes and cardiovascular mortality: the impact of sex
Norhammar A
Letter: DIABETES CARE. 2018;41(6):e106-e108
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Thuresson M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jorgensen ME; Wittbrodt E; Hammar N; Fenici P; Kosiborod M
Letter: DIABETES CARE. 2018;41(6):e104-e105
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Nystrom T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Letter: CIRCULATION. 2018;137(9):989-991
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jorgensen ME; Thuresson M; Arya N; Bodegard J; Hammar N; Fenici P
Corrigendum: THE LANCET DIABETES AND ENDOCRINOLOGY. 2018;6(7):E6
Diabetes and cardiovascular mortality: the impact of sex (vol 6, pg 517, 2018)
Norhammar A
Editorial comment: CARDIOLOGY. 2016;134(4):411-412
Problems, Pitfalls and Encouraging Information on Patients with Diabetes and Heart Failure
Norhammar A; Johansson I; Ryden L
Editorial comment: EUROPEAN HEART JOURNAL. 2015;36(16):951-952
EACPR country of the month initiative: Sweden The structure of health care in Sweden
Kiessling A; Hambraeus K; Held C; Norhammar A; Perk J
Review: DIABETOLOGIA. 2013;56(1):1-9
Type 2 diabetes and cardiovascular disease in women
Norhammar A; Schenck-Gustafsson K
Review: DIABETES AND VASCULAR DISEASE RESEARCH. 2008;5(4):285-290
Implications of abnormal glucose metabolism in patients with coronary artery disease
Anselmino M; Wallander M; Norhammar A; Mellbin L; Ryden L
Letter: EUROPEAN HEART JOURNAL. 2008;29(16):2058-2059
Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus:: when to start it?
Mellbin LG; Ryden L; Malmberg K; Norhammar A; Wedel H
Letter: HEART. 2008;94(7):935
Not only after myocardial infarction -: Reply
Norhammar A; Ryden L
Letter: EUROPEAN HEART JOURNAL. 2008;29(8):1076-1077
Glucose, insulin, and coronary heart disease:: reply
Mellbin LG; Malmberg K; Norhammar A; Ryden L
Published conference paper: JOURNAL OF INTERNAL MEDICINE. 2007;262(2):145-156
Hyperglycaemia and cardiovascular disease.
Bartnik M; Norhammar A; Rydén L
Other: LAKARTIDNINGEN. 2006;103(47):3734-3738
[Diabetes and myocardial infarction: intensive glucose control important according to international guidelines].
Norhammar A; Malmberg K; Mellbin L; Rydén L
Thesis / dissertation: 2003
Diabetes mellitus, glucose abnormalities and acute coronary syndromes : studies on prevalence, risk and impact of treatment
Norhammar, Anna
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:539
Impaired glucose tolerance and diabetes mellitus; very common in patients with acute coronary syndromes
Bartnik M; Malmberg K; Nilsson G; Norhammar A; Tenerz A; Ryden L
Published conference paper: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2001;498:279-284
Insulin treatment post myocardial infarction:: The Digami study
Malmberg K; Norhammar A; Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 2000;21(16):1293-1294
Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome
Norhammar A; Malmberg K
Visa fler

Anställningar

Adjungerad Professor, Medicin, Solna, Karolinska Institutet, 2019-2027

Examina och utbildning

Docent, Kardiologi, Karolinska Institutet, 2010
MEDICINE DOKTORSEXAMEN, Institutionen för medicin, Solna, Karolinska Institutet, 2003

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI